RxDoctor Payments Data

Anil Kankaria

Gastroenterology · Hollywood, MDNPI 1568497535

Payments from drug & device makers

$6,993in general payments, 2019–2025

Across 261 payments — averaging $26.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$1K
  • Johnson & Johnson$794
  • Sanofi$391
  • Madrigal Pharmaceuticals$377
  • Takeda Pharmaceuticals U.S.A., Inc.$272
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$120%
  • Speaking & faculty fees$2,35034%
  • Food & beverage$4,50564%
  • Education$1262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,993 in reported general payments places this provider in the 65th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$187,284
Medicare patients
591
Services billed
1,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase23$63,185
LinzessLinaclotide56$40,063
ClenpiqSod Picosulf/Mag Ox/Citric Ac87$14,820
Budesonide EcBudesonide15$9,697
Famotidine243$3,496
Lubiprostone11$2,306
Omeprazole140$2,139
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,761
Budesonide DrBudesonide21$1,359
CholestyramineCholestyramine (With Sugar)17$1,330
Pantoprazole Sodium72$1,188
Colestipol Hcl18$1,063
Sucralfate31$938
Dicyclomine Hcl38$519
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl30$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,316$103,24879 claims
Ferring Pharmaceuticals Inc.Clenpiq$264$14,82087 claims
Braintree Laboratories, Inc.Sutab$28$1,76111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Hollywood

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →